Eli Lilly shares rose 4.1% on Wednesday after the Food and Drug Administration approved Foundayo, its once-daily oral obesity drug. This approval is a big step in the competition for leadership in the fast-growing obesity drug market. Meanwhile, Novo Nordisk’s American depositary receipts fell 0.4% after the news. The difference in stock movement shows the pressure Lilly is exerting on its competitors in the obesity treatment market.

Foundayo will first be available through Lilly’s LillyDirect platform. Shipping will start on April 6. After that, it will be sold in retail pharmacies and through telehealth. This launch is more than a regulatory step; it starts a new chapter in the oral obesity drug market. Novo already sells an oral version of Wegovy. Foundayo does not have the same use restrictions as Novo’s drug. Novo’s drug must be taken on an empty stomach, with little water, and requires a 30-minute wait before eating. Without these limits, Foundayo offers patients more convenience. This advantage could help Foundayo gain wider use.

The competition is about more than convenience. In February, Novo faced a setback. Its experimental obesity drug, CagriSema, did not perform better than Lilly’s tirzepatide in a direct comparison. This result hurt confidence in Novo’s future products. It also strengthened Lilly’s reputation as a leader. Other companies are joining the race. Amgen, for example, is working on a once-monthly injectable. If available, it could further divide the market.

The difference in stock performance between Lilly and Novo over the past year is clear. Lilly’s shares are up about 17%. Novo’s U.S.-listed shares have dropped more than 46%. Both stocks have fallen so far in 2026. Lilly is down about 11%. Novo is down 28%. The market-value gap is large. On Wednesday, Lilly’s market cap was about $869 billion. Novo’s was $158.2 billion. This big difference shows investors believe Lilly is leading the race in obesity drugs.

Analysts see Foundayo’s approval as a key event. It strengthens Lilly’s lead. Now, Lilly can compete with Novo in both injectable and oral drugs. Patients and doctors have more treatment options. The stock’s move on Wednesday suggests the market sees Lilly pulling ahead. Novo is facing its toughest competition in years.